Transgene Biotek
2.85
-0.18(-5.94%)
Market Cap₹21.63 Cr
PE Ratio-12.12
Company Performance:
1D-5.94%
1M+24.45%
6M-31.65%
1Y-27.11%
5Y-41.84%
View Company Insightsright
More news about Transgene Biotek
03Feb 26
Transgene Biotech Limited Faces SEBI Recovery Proceedings Over Rs.38 Lacs Penalty Default
Transgene Biotech Limited has disclosed receiving SEBI's prohibitory order RRD/SRO/1166/2026/1 for recovery of Rs.38 lacs penalty from a June 27, 2022 adjudication order. The order has frozen all bank accounts and prohibited disposal of company assets, causing complete operational paralysis including salary payment suspension. Despite having filed an appeal with Securities Appellate Tribunal on October 7, 2022, which remains pending, the recovery proceedings have brought all business activities to a standstill.
 no imag found
14Nov 25
Transgene Biotek Reports Net Loss and Approves Key Board Decisions
Transgene Biotek Limited reported a net loss of Rs. 38.84 lakhs for Q2 FY2026 ending September 30, 2025, with revenue of Rs. 5.28 lakhs and expenses of Rs. 44.12 lakhs. The company's 35th AGM is scheduled for December 30, 2025. The board approved reappointments of key directors, including Dr. K. Koteswara Rao as Chairman & Managing Director. Ongoing legal challenges include hearings at SAT Mumbai and Appellate Tribunal New Delhi, and an appeal at NCLT Hyderabad.
 no imag found
17Oct 25
Transgene Biotek Faces Legal Challenge at NCLT Over Rs 6.82 Crore Unpaid Loan
Transgene Biotek, a biotechnology company in Telangana, India, is facing a legal case at the NCLT Hyderabad Bench. Babaji Nethralayya Private Ltd has filed a case for an unpaid loan of Rs 6.82 crore plus interest. The company acknowledged the proceedings in a BSE filing and stated efforts are being made to resolve the matter amicably. The next hearing is scheduled for December 16, 2025.
 no imag found
07Aug 25
Transgene Biotek Reports Q1 Loss, Appoints New Auditors Amid Ongoing Regulatory Challenges
Transgene Biotek Limited reported a net loss of Rs 43.37 lakhs in Q1, compared to a profit of Rs 19.94 lakhs in the same period last year. Revenue from operations slightly increased to Rs 4.95 lakhs. The company appointed new Internal and Secretarial Auditors. Regulatory challenges persist, with ongoing proceedings at the Securities Appellate Tribunal and Appellate Tribunal in New Delhi. The company cleared the principal sum owed to BIRAC but faces operational difficulties due to regulatory issues.
 no imag found
Transgene Biotek
2.85
-0.18
(-5.94%)
1 Year Returns:-27.11%
Industry Peers
Dr. Lal Path Labs
1,408.90
(-1.54%)
Vijaya Diagnostic Centre
1,065.55
(+3.50%)
Metropolis Healthcare
467.10
(-1.08%)
Krsnaa Diagnostics
601.05
(-1.70%)
Suraksha Diagnostic
282.48
(+0.64%)
3B BlackBio DX
1,322.35
(+2.36%)
Sastasundar Ventures
268.80
(-0.17%)